Study on changes in urinary glucose concentrations in Type 2 diabetes patients treated with the selective SGLT2 inhibitor luseogliflozi
- Conditions
- Patients with Type 2 diabetes
- Registration Number
- JPRN-UMIN000018806
- Lead Sponsor
- Medical corporation Jinnouchi society Jinnouchi Hospital
- Brief Summary
The urine sugar discharge amount changed significantly before and luseogliflozin taking starting, but after it began there were slightly fluctuations. A weight change was a plateau after starting after 3 months, but I can think it doesn't depend on decline of the urine sugar discharge amount. Improvement of the numerical value related to insulin resistance was seen more than the 3rd month.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
(1) Patients diagnosed with diabetes other than Type 2 diabetes, including Type 1 diabetes, diabetes associated with diseases other than Type 2 diabetes and gestational diabetes (2) Patients with severe renal function impairment, including nephrotic syndrome, renal failure and dialysis (3) Patients with severe hepatic function impairment, including cirrhosis (4) Patients with severe heart diseases, including heart failure, myocardial infarction and cerebral infarction, or patients with prior history of any of these diseases during the past 6 months (5) Patients with severe diabetic microvascular diseases, including diabetic retinopathy and diabetic neuropathy that does not sufficiently respond to treatment (6) Patients with concurrent or prior history of malignant tumors, excluding those not receiving treatment for their disease and who have not experienced recurrence and those who are not likely to experience recurrence during participation in the study (7) Patients who have previously developed hypersensitivity to luseogliflozin (8) Patients who are alcoholics (9) Females who are pregnant or are likely to be pregnant, or those who want to become pregnant during participation in the study and nursing mothers (10) Patients who the physician in charge determines as ineligible for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rinary glucose level, CGM, HbA1c, fasting blood glucose level and body weight from before the start of treatment until completion (Week 24) or discontinuation of treatment
- Secondary Outcome Measures
Name Time Method rine volume at measurement of urinary glucose, subcutaneous fat, visceral fat, insulin, EPA/AA ratio, FFA, ghrelin, blood ketone bodies, 1.5-anhydro-D-glucitol, and QOL from before the start of treatment until completion (Week 24) or discontinuation of treatment